The Gene and Cell Therapies Targeting CNS Disorders Market is set to witness immense growth during the forecast period 2022-2028. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufacturers/players/vendors analysis, segments & sub-segments, and forecast. The report also focuses on market drivers, challenges (current and future), revenue growth, future roadmap, standardization, deployment models, and forecast analysis.
Overview:
One of the most common cancers of the CNS is glioblastoma. This deadly tumor is composed primarily of immune cells known as B and T cells. While B and T cells have different frequencies, both cells are present in a small proportion of tumors. In a healthy CNS, B cells are absent. They are, however, present in the CSF. Viruses can enter the CNS through several routes. Some viruses enter the CNS via the bloodstream and lymphoid tissues. In addition, arboviruses enter the skin after an insect bite. Langerhans cells pick up the virus and migrate to the draining lymph node. The virus then sheds its infectious particles into the bloodstream, where it can cause systemic infection. So, preventing CNS infections is essential for human health.
The global gene and cell therapies targeting CNS disorders market focus on six regions, such as North America, Asia Pacific, South America, Europe, the Middle East, and Africa.
Drivers:
The increasing incidence of neurological disorders in the world is expected to fuel the growth of the global gene and cell therapies targeting CNS disorders market over the forecast period. For instance, according to Neurological Alliance, 14.7 million individuals in the world suffer from neurological cases. New research in nanotechnology is bringing new hope to the fight against CNS diseases. In fact, nanotechnology has radically changed the treatment of neurological diseases. It has helped improve the diagnosis and treatment of many conditions by targeting the cause of the disease. It has also improved the quality of life for many people. The aim of this research is to develop new drugs that target CNS cells and improve their treatment. It will also make treatment for CNS disorders more effective than ever. Moreover, the high development in the biotechnology sector is estimated to enhance the growth of the global gene and cell therapies targeting CNS disorders market.
Restraints:
The high cost of gene therapies and cell therapies is expected to hinder the growth of the global gene and cell therapies targeting CNS disorders market.
Regional Insights:
In regions, North America is expected to hold a major share of the global gene and cell therapies targeting CNS disorders market, owing to the high developments of biotechnology companies in the region. For instance, according to Seed Scientific, there are around 6,600 biotechnology companies in the United States currently. Moreover, the Asia Pacific is estimated to witness significant growth in the global gene and cell therapies targeting CNS disorders market owing to the high incidence of nervous system disorders in the region. The expansion of the healthcare sector in the region is assessed to drive market growth.
Competitive Section:
Key players operating in the global gene and cell therapies targeting CNS disorders market include UniQure Biopharma, StemCyte, Hoffmann-La Roche, NeuroGeneration, Sio Gene Therapies, Longeveron, Sangamo Therapeutics, Stemedica Cell Technologies, Ferrer Internacional, Neuralstem, Neuroplast, Libella Gene Therapeutics, Rapa Therapeutics, Helixmith, Q Therapeutics, Corestem, Eli Lilly and Company, BrainStorm Cell Therapeutics, and Novartis.
Gene and Cell Therapies Targeting CNS Disorders Market Dynamics:
This market study estimates the market size in terms of both value (million USD) and volume (K Units). The Gene and Cell Therapies Targeting CNS Disorders Market report analyses market trends based on historical data and the latest developments. It provides both qualitative and quantitative data on the elements that will shape the market's growth from 2022 to 2028. The market capacity and consumption potential of major companies are discussed in this research report. Furthermore, it concentrates on prominent regions (Latin America, Europe, Asia Pacific, Africa, and the Middle East). Also, the report evaluates COVID-19's impact on the Gene and Cell Therapies Targeting CNS Disorders Market.
Companies profiled in the Gene and Cell Therapies Targeting CNS Disorders Market report include:
- Novartis
- BrainStorm Cell Therapeutics
- Corestem
- Q Therapeutics
- Helixmith
- Rapa Therapeutics
- Neuroplast
- StemCyte
- Ferrer Internacional
- Neuralstem
- Ferrer Internacional
- Stemedica Cell Technologies
- Libella Gene Therapeutics
- Sangamo Therapeutics
- Hoffmann-La Roche
- Longeveron
- Sio Gene Therapies
- Eli Lilly and Company
- NeuroGeneration
- Brain Neurotherapy Bio (AskBio)
- UniQure Biopharma
The report covers extensive competitive intelligence which includes the following data points:
⇨ Business Overview
⇨ Business Model
⇨ Financial Data
⇨ Financial – Existing
⇨ Financial – Funding
⇨ Product/Service Segment Analysis and specification
⇨ Recent Development and Company Strategy Analysis
⇨ SWOT Analysis
Segmentation by Type:
The type segment contributed the largest share to the Gene and Cell Therapies Targeting CNS Disorders Market in 2021; this segment is projected to grow at the highest CAGR from 2022 to 2028.
- Gene Therapy
- Cell Therapy
Segmentation by Application:
An end-use industry is projected to grow at the highest CAGR during the forecast period, due to rapid development in emerging economies North America, APAC, MEA, Europe, and ROW.
- Alzheimer's Disease (AD)
- Huntington's Disease (HD)
- Parkinson's Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease
- Multiple Sclerosis (MS)
- Adrenoleukodystrophy & Metachromatic Leukodystrophy
- Neuropathies
- Batten Disease (BD)
Key Benefits for Stakeholders:
- The study represents a quantitative analysis of the present Gene and Cell Therapies Targeting CNS Disorders Market trends, estimations, and dynamics of the market size from 2022 to 2028 to determine the most promising opportunities.
- Porter's five forces study emphasizes the importance of buyers and suppliers in assisting stakeholders to make profitable business decisions and expand their supplier-buyer network.
- In-depth analysis, as well as market size and segmentation, help you identify current Gene and Cell Therapies Targeting CNS Disorders Market opportunities.
- The largest countries in each region are mapped according to their revenue contribution to the market.
- The Gene and Cell Therapies Targeting CNS Disorders Market research report gives a thorough analysis of the current status of the Gene and Cell Therapies Targeting CNS Disorders Market's major players.
Reasons to Purchase Gene and Cell Therapies Targeting CNS Disorders Market Report:
- Both current and future prospects for the Gene and Cell Therapies Targeting CNS Disorders Market in developed and emerging markets.
- Analysis of various perspectives of the market with the help of Porter’s five forces analysis.
- During the forecast period, major regions are expected to see the most rapid increase.
- Identify the most recent advancements, Gene and Cell Therapies Targeting CNS Disorders Market shares, and top market players' strategies.
Research Methodology:
To estimate and validate the size of the Gene and Cell Therapies Targeting CNS Disorders Market and many other dependent submarkets in the overall market, both top-down and bottom-up methodologies are utilized. Key players in the market have been identified through secondary research and their market shares have been determined through primary and secondary research. Secondary sources and verified primary sources were used to determine all percentage share splits and breakdowns.
Request Discount 
Inquire Before Buy
